On February 24, 2026, Novo Nordisk announced it is cutting the US list price of Wegovy and Ozempic by up to 50 percent, down to $675 a month, effective January 1, 2027. The move is a direct response to Eli Lilly's Zepbound, which lists at $1,086 and has been taking market share (Bloomberg, CNBC, CNN, Forbes). At the same time, the Trump administration's Most-Favored-Nation deal with Lilly and Novo has already set Medicare and Medicaid pricing at $245 a month, with a $50 patient copay, for Ozempic, Wegovy, Mounjaro and Zepbound. A new TrumpRx direct-to-consumer option is launching around $350 a month and is expected to drift toward $245 (AJMC, AMCP.org, PBS).
If you run a medical weight loss or GLP-1 clinic, this is not background noise. It is a pricing floor your cash-pay program now has to answer for in every ad, every landing page, and every phone call. At the same moment prices are collapsing, regulators are tightening the screws on how this category can advertise at all. Both shifts change what marketing has to do in 2026. Here is how to handle it.
How Does the Wegovy and Ozempic Price Cut Change What Clinics Should Advertise?
It means your marketing can no longer lead with "affordable GLP-1s" without immediately answering the obvious question: affordable compared to what. With list prices dropping to $675 a month by January 2027 and Medicare/Medicaid patients already paying as little as $50 a month under the Most-Favored-Nation deal, and a TrumpRx self-pay option trending toward $245, a clinic charging a premium for a compounded or brand program needs a reason beyond price that a prospective patient will actually believe.
Practically, this means your ads and landing pages need to shift from price-anchored messaging to value-anchored messaging: physician oversight, dosing titration, side effect management, nutrition and strength coaching bundled with the medication, and speed of access compared to a crowded primary care system. If your entire funnel is built around "cheaper GLP-1s here," that funnel has an expiration date, and it is not far off.
What Compliance Rules Actually Apply to GLP-1 Advertising Right Now?
The direct answer is that federal regulators are actively enforcing against exactly the tactics this category has relied on for the past three years, so any campaign built on compounded drug claims, fake testimonials, or vague subscription pricing is now a legal and platform risk, not just an ethics question.
On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, which would close the loophole that let compounding pharmacies keep producing these drugs after the official shortage ended (Orrick, Stanford Medicine). In February and March 2026, the FDA sent warning letters to more than 30 telehealth companies over how they were marketing compounded GLP-1 products. The FTC finalized its order against telehealth provider NextMed on December 3, 2025, over deceptive weight-loss advertising, fabricated testimonials, and undisclosed subscription billing (FTC.gov). And on December 17, 2025, a bipartisan coalition of 35 state attorneys general sent Meta a letter demanding it restrict weight-loss drug ads to FDA-approved products only and ban AI-generated before-and-after imagery in ad creative.
For a clinic, this translates into a short checklist before any campaign goes live: only advertise FDA-approved medications by name unless your compounding is fully compliant with the narrowing 503B rules, never use AI-generated or stock before-and-after photos, disclose subscription billing terms clearly and up front, and keep testimonials real, documented, and consent-verified. Assume every ad is being screened against the NextMed order as the new baseline for what "deceptive" looks like.
What Do Google and Meta Actually Require Before You Can Run GLP-1 Ads?
Google's October 2025 Healthcare and Medicines policy update made LegitScript certification effectively mandatory for anyone advertising GLP-1 or weight-loss treatments, and that certification process takes four to eight weeks, so clinics need to start it well before a launch date, not the week they want to go live. The same update added explicit rules against ambiguous subscription pricing, meaning your ad copy and landing page pricing need to match exactly, with no "starting at" language that hides the real monthly cost.
If you have not started LegitScript certification yet, that is the first task, not the ad account setup. Google will reject or suspend healthcare advertisers who try to run GLP-1 campaigns without it, and a suspended account mid-quarter is far more costly than the weeks spent getting certified.
Meta vs Google: Where Should a Medical Weight Loss Clinic Actually Spend Its Ad Budget?
The direct answer is that Google should carry the majority of a GLP-1 clinic's budget because it captures people already searching with medical intent, while Meta should be used for a smaller, tightly controlled slice focused on retargeting and educational content, because Meta's ad policies and current AG pressure make direct-response weight-loss creative a higher-risk, lower-efficiency channel right now.
Google is good for: capturing high-intent search traffic from people typing "GLP-1 clinic near me" or "semaglutide program cost," Local Service Ads for clinics with a physical location, and Performance Max campaigns once LegitScript certification is in place. It is bad for top-of-funnel awareness building, since search ads only work when someone is already looking.
Google's specific restriction: LegitScript certification is effectively required as of the October 2025 policy update, and healthcare advertisers without it will see ads disapproved or accounts flagged. Budget for the four-to-eight-week approval window before you plan a launch date.
Meta is good for: retargeting website visitors who did not convert, building an educated audience through carousel and video content about the medical process, and running lookalike audiences off an existing patient list, where allowed under your platform's health-data handling rules. It is bad for cold, direct-response prospecting in this category right now, because the December 2025 letter from 35 state attorneys general specifically pushed Meta to restrict weight-loss drug ads to FDA-approved products and ban AI-generated before-and-after content. Whether or not Meta has fully implemented every demand in that letter, expect enforcement to tighten through 2026, not loosen.
The split we recommend: put 60 to 70 percent of paid budget in Google Search and Local Service Ads, where intent is already established and the LegitScript gate filters out a lot of the noise your competitors are fighting through. Put the remaining 30 to 40 percent in Meta, but restrict it to retargeting warm traffic and organic-style educational content rather than cold acquisition with dramatic transformation imagery. That imagery is precisely what regulators are targeting.
What Should Clinics Do About AI Search and ChatGPT Citations?
Be honest with yourself here: there is no credible published data yet showing individual clinics being cited by ChatGPT or Google AI Overviews for weight loss queries. The one real index tracking AI citation activity, from 5W, explicitly excludes telehealth and clinic-level businesses from its category coverage. Anyone telling you they can guarantee your clinic shows up in AI Overviews is selling you something that cannot currently be measured or verified at the individual business level.
What you can do instead, and what does move the needle regardless of AI search: publish clear, medically accurate FAQ content that answers the real questions patients search for, structure that content with proper schema markup, keep your Google Business Profile complete and active with real reviews, and build the kind of clear, well-organized site that both human patients and any future AI retrieval system will find easy to parse. Build for today's searchers first. The AI citation layer will follow good fundamentals, not chase them.
How Should a Clinic Actually Position Itself in This Market Right Now?
The direct answer is to compete on access, clinical oversight, and program structure rather than on raw drug price, because the price floor is now set by Medicare, Medicaid, and TrumpRx, and no cash-pay clinic can out-discount a $245-a-month federal program.
That means your marketing should emphasize what a government program cannot offer: same-week appointments instead of a months-long wait, a physician who actually manages dosing and side effects rather than a script and a shrug, and a program that includes nutrition, labs, and follow-up rather than just a prescription. Say this plainly on your landing pages and in your ad copy. Patients comparing $245 government pricing against your program need a real answer for the gap, not a vague promise of better service.
If you want help building a campaign that handles the LegitScript process, the Google-versus-Meta split, and compliant creative all at once, PELORA Marketing runs medical weight loss and GLP-1 clinic marketing built specifically around this shifting regulatory and pricing environment.
Want a marketing plan built for this category specifically?
PELORA runs paid media, creative, and compliance-aware campaigns built around what's actually allowed and what actually works in your category, not generic playbooks.
Get the free audit → See our work in this categoryFAQCommon questions
Does my clinic need LegitScript certification to run Google ads for GLP-1 treatments?
Yes. Google's October 2025 Healthcare and Medicines policy update made LegitScript certification effectively mandatory for GLP-1 and weight-loss advertisers, and approval takes four to eight weeks, so start the process before you plan an ad launch date.
Can compounded semaglutide or tirzepatide still be advertised legally?
The ground is shifting fast. The FDA proposed on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, which would close the shortage-era loophole compounders have relied on, and the FDA has already sent warning letters to more than 30 telehealth companies over how they marketed compounded GLP-1 products. Any clinic still marketing compounded versions should get current legal guidance before running ads.
Will the new lower drug prices hurt cash-pay clinic revenue?
They put real pressure on price-based positioning. With list prices for Wegovy and Ozempic dropping to $675 a month by 2027, and government-backed pricing already as low as $245 a month with a $50 copay, clinics that compete purely on discounted pricing will struggle. Clinics that compete on access speed, physician oversight, and program structure have a stronger position.
Is Meta or Google better for GLP-1 clinic advertising?
Google is generally the stronger primary channel because it captures people already searching with medical intent, while Meta works best as a smaller retargeting and education channel given the current advertiser scrutiny, including the December 2025 letter from 35 state attorneys general pushing Meta to restrict weight-loss drug ads and ban AI-generated before-and-after content.
Last updated August 14, 2026. By Preston Durnford. Newport Beach, California. General information only, not legal, medical, or financial advice.